Design Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparisons are with the three months ended March 31, 2022. Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC small molecules for inherited nucleotide repeat expansion diseases. It has no approved products and reported no product revenue.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $15.7 million | $8.8 million |
| General and administrative expense | $5.9 million | $4.6 million |
| Total operating expenses | $21.7 million | $13.4 million |
| Net loss | $19.3 million; $0.35 per share | $13.3 million; $0.24 per share |
| Net cash used in operating activities | $17.4 million | $11.8 million |
| Cash, cash equivalents and investment securities | $315.4 million | $330.4 million at Dec. 31, 2022 |
| Total assets / total liabilities | $324.7 million / $11.9 million | $341.1 million / $13.8 million at Dec. 31, 2022 |
Cash and cash equivalents were $28.8 million and investment securities were $286.6 million at March 31, 2023. Current assets were $318.9 million versus current liabilities of $9.0 million. The filing reports no debt. Operating margins are not meaningful given the absence of revenue. Comprehensive loss was $17.9 million, reflecting a $1.4 million unrealized gain on available-for-sale securities.
Material changes versus prior comparable period
- Operating expenses rose $8.3 million, or about 62%; R&D increased $7.0 million, or about 80%, primarily from DT-216 clinical development, early-stage programs, and higher personnel costs.
- G&A increased $1.3 million, or about 28%, mainly due to personnel costs. Stock-based compensation totaled $3.4 million, up from $2.4 million.
- Net loss increased $6.0 million, or about 45%. Other income, net, rose to $2.4 million from $0.1 million.
- Operating cash use increased $5.6 million. Cash and investments declined $15.0 million from year-end, principally due to operating spend; investing cash inflow largely reflected maturities of securities.
Outlook, development, and risks
- Management expects continued and increasing operating losses and R&D spending. It estimates available cash and investments will fund planned operating expenses and capital expenditures for more than 12 months after the filing, but not through regulatory approval of its candidates; additional capital will be required.
- DT-216, the Friedreich ataxia (FA) candidate, is in an ongoing Phase 1 multiple-ascending-dose trial. Management cited December 2022 single-dose initial results as generally well tolerated and showing increased FXN mRNA, including a greater-than-two-fold increase in the cohort with the highest response. A Phase 2 trial was expected to begin in the second half of 2023.
- DT-168 for Fuchs endothelial corneal dystrophy (FECD) was nominated in December 2022; the company planned additional preclinical work and an IND submission in the second half of 2023. For its DM1 program, it expected to complete IND-enabling studies and submit an IND in 2024.
- In the DT-216 single-dose trial, three patients had mild or moderate injection-site thrombophlebitis that resolved without treatment. The filing cautions that early and interim results may change and may not predict later trial outcomes.
- FDA approval of omaveloxolone for FA in February 2023 could affect DT-216 trial enrollment and competition. Other principal risks include clinical and regulatory uncertainty, manufacturing and third-party dependencies, potential financing dilution, and macroeconomic or banking disruptions.
- The company had not used its $100 million at-the-market program as of March 31, 2023. It disclosed related-party leases and consulting arrangements. No material contingent liabilities or material litigation were reported; disclosure controls were assessed as effective.
Most important facts for investors to verify
- Progress, safety, and complete data from the DT-216 multiple-dose trial, and whether the anticipated Phase 2 start occurred on schedule.
- Whether the planned DT-168 IND submission and DM1 development milestones were achieved, and the costs and timing of those programs.
- Cash burn, investment balances, and management’s runway assumptions relative to clinical development spending and the need for further financing.
- Effects of omaveloxolone and other competing FA treatments on enrollment, trial design, and DT-216’s prospects.
- Potential dilution if the company raises capital, and the terms and obligations associated with its related-party arrangements and WARF license, which includes up to $17.5 million in future milestone payments.